Compare · ESTA vs SNN
ESTA vs SNN
Side-by-side comparison of Establishment Labs Holdings Inc. (ESTA) and Smith & Nephew SNATS Inc. (SNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ESTA and SNN operate in Industrial Specialties (Health Care), so they compete in similar markets.
- SNN is the larger of the two at $12.18B, about 6.7x ESTA ($1.83B).
- SNN has been more active in the news (11 items in the past 4 weeks vs 9 for ESTA).
- SNN has more recent analyst coverage (25 ratings vs 15 for ESTA).
- Company
- Establishment Labs Holdings Inc.
- Smith & Nephew SNATS Inc.
- Price
- -
- -
- Market cap
- $1.83B
- $12.18B
- 1M return
- -
- +4.57%
- 1Y return
- -
- -19.99%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 9
- 11
- Recent ratings
- 15
- 25
Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Smith & Nephew SNATS Inc.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
Latest ESTA
- Stifel initiated coverage on Establishment Labs with a new price target
- SEC Form 8-K filed by Establishment Labs Holdings Inc.
- Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®
- Director Gillin Leslie was granted 262 shares, increasing direct ownership by 1% to 18,856 units (SEC Form 4)
- Director Schutter Edward J was granted 253 shares, increasing direct ownership by 0.14% to 178,205 units (SEC Form 4)
- Director Lewin Nicholas Sheridan was granted 389 shares, increasing direct ownership by 0.04% to 1,080,349 units (SEC Form 4)
- Director Slotkin Bryan was granted 253 shares, increasing direct ownership by 0.77% to 33,052 units (SEC Form 4)
- Director Custin Ann was granted 301 shares, increasing direct ownership by 1% to 24,626 units (SEC Form 4)
- Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants
- Chief Executive Officer Caldini Filippo covered exercise/tax liability with 682 shares, decreasing direct ownership by 1% to 48,829 units (SEC Form 4) (tax liability)
Latest SNN
- SEC Form S-8 filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal
- Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
- Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
- Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
- Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System